Atlas Trials

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Clinical trial NCT05432804 · RECRUITING

Trial details

NCT number
NCT05432804
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
Start date
2023-03-20
Primary completion
2027-06-30
Enrollment
97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.